Physicians remain wary of the wellness trend ...
In hormone receptor (HR)–positive, HER2-negative advanced breast cancer, starting CDK4/6 inhibitors (CDK4/6i) in the first ...
USD 11.58 billion; 2031 Projected Market Size: USD 16.39 billion; CAGR (2026–2031): 7.2%; Chemiluminescence Immun ...
According to MarketsandMarkets, the Chemiluminescence Immunoassay Market is projected to grow from about USD 11.58 billion in 2026 to USD 16.39 ...
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript March 5, 2026 TriSalus Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.13.
February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...
Dr. Kasey Holland Hamski, ND A case illustrating the interplay between EBV reactivation, environmental mold exposure, and ...
Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...
Few topics provoke as much concern as the perception that puberty is beginning earlier than ever. While synthetic ...
A report from the world's leading scientific and medical experts on hormone-related health conditions raises new concerns about the profound threats to human health from endocrine disrupting chemicals ...
Canfor (TSE:CFP) management used its fourth-quarter 2025 results call to outline ongoing pressure from weak lumber and pulp ...
In a joint guidance document issued by the European Society for Paediatric Endocrinology and European Society of ...